The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma
Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, discusses the results of the TOURMALINE-MM3 trial (NCT02181413) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Maintenance therapy with ixazomib, an oral proteasome inhibitor, was found to significantly prolong progression-free survival following autologous stem cell transplantation in newly diagnosed multiple myeloma.
